Rationale: Purinergic signaling plays an important role in inflammation and vascular integrity, but little is known about purinergic mechanisms during the pathogenesis of atherosclerosis in humans.
INTRODUCTION
Although atherosclerosis is a widely studied disease and extensive interventions are practiced, it still remains a major cause of death in Western societies. 1 The contemporary view of the disease as an inflammatory process of the vascular wall is well-established and reviewed in several excellent articles. [1] [2] [3] The importance of extracellular purinergic signaling or metabolic pathways (i.e., the conversion of circulating ATP and ADP to AMP, and then to adenosine, by cell surface-associated and soluble nucleotidases) in inflammation and cell trafficking is acknowledged. [4] [5] [6] [7] Moreover, based on preclinical findings, evidence suggests that purinergic signaling plays an important role in atherosclerosis. 8, 9 The first such findings from human samples were reported by Lecka et al. in 2010 10 , and strikingly, recent human genetic studies indicate that NT5E (ecto-5'-nucleotidase/CD73) mutations are an important factor contributing to peripheral arterial calcification. 11 Thus, there is compelling evidence for the role of extracellular ATP metabolism in vascular inflammation, but in a broader spectrum, very little is known about the contribution of purinergic signaling in atherosclerosis.
Endogenous nucleotides, ATP and ADP, are released into circulation from cells under stress and injury. After release, they create an important signaling cascade to modulate vascular tone, platelet aggregation, and inflammation. 12, 13 Firstly, the endothelial cell surface enzyme nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, also known as CD39) converts ATP to ADP, and further to AMP. ADP is the most significant mediator of platelet aggregation via activation of the P2Y 12 receptor expressed on platelets, and the clearance of ADP via NTPDase1/CD39 is crucial for thromboregulation. [14] [15] [16] Subsequent breakdown of ATP/ADP-derived AMP to adenosine is mediated by another enzyme, ecto-5'-nucleotidase/CD73. general population cohort of FINRISK 1997 19 (see Online Supplement for further details). Controls had to be free of chronic heart diseases, PAD, stroke, diabetes, cancer, chronic obstructive pulmonary disease (COPD), and rheumatic illnesses both on the basis of a self-report and register linkage with national health care databases.
Blood samples.
Samples were drawn in the morning after at least 4 hr of fasting. Two 9 mL samples of whole blood were obtained, and each sample was placed in a serum sample tube or EDTA sample tube and handled as described in the Online Supplement.
Quantification of ATP and ADP levels in human plasma. Plasma ATP and ADP levels were determined using an ATPlite enzyme-coupled assay kit with a long-lived luminescent signal (Perkin Elmer, Groningen, The Netherlands) as described previously 20 , with further details in the Online Supplement.
Measurement of soluble nucleotidase activity in human serum.
Soluble ADPase/NTPDase and 5'-nucleotidase activities were assayed radiochemically, as described previously 21 , with further details in the Online Supplement.
Statistical analyses.
Statistical analyses were performed in association with a professional statistical provider, 4Pharma Ltd. (Turku, Finland). First, simple distributional characteristics of purinergic signaling markers were compared between the controls and the patient cohort. Markers with skewed distributions were log-transformed to better fit to normality, which was tested using a Shapiro-Wilk test. The patient cohort was analyzed according to different subgroups and background variables, and compared against other subgroups or the controls using a t-test for normally distributed variables (including log-transformed data). Pearson correlations were used to study the associations of continuous variables. Linear regression models were used to study the possible trends in the means of log-transformed marker values across PAD localization and the association of markers to age as a continuous variable.
After comparing the controls and the patient cohort, further explorative statistical modeling was performed using only the patient cohort. First, based on univariate analysis the associations of suspected cardiovascular risk factors (for CD39: smoking, COPD, hypoxia, uremia, renal insufficiency, and hypertension; for CD73: hypoxia, renal insufficiency, uremia; for ATP and ADP: smoking and hypertension) to log-transformed markers were tested individually in linear regression models containing gender, age group and PAD localization as fixed effects, and P-AFOS as a covariate. In addition, the associations of used medications (aspirin, beta-blockers, angiotensin converting enzyme (ACE) blockers, calcium channel blockers, furosemide, warfarin, nitroglycerin, metformin, oral or inhaled cortisone, angiotensin receptor blockers (ARBs), bisphosphonates and gliptins) to log-transformed markers were tested individually in linear regression models containing gender, age group, PAD classification, statin use, and clopidogrel use as fixed effects, and P-AFOS as a covariate. A stepwise backward elimination method was applied for all the above-mentioned models. The variable under question was retained in the model even when fulfilling the elimination criterion to examine its significance in the final reduced model. Second, the identified factors appearing to be related to the marker were then selected for the final multivariate model incorporating all the selected factors, and gender, age group, PAD localization and P-AFOS. This full combined model was then simplified to a reduced model using the backward elimination approach leaving only statistically significant factors into the model. In summary, we first tested cardiovascular risk factors and medications separately in the linear regression model. From these factors, a combined model was formed encompassing all factors that had shown significance. Finally, a backward elimination method was applied to the combined model to determine the most decisive factors affecting marker levels.
No P-value adjustments were performed. A P-value of 0.05 was used as the threshold for statistical significance. All statistical analyses were performed using SAS Software for Windows version 9.3.
RESULTS

Description of the patient cohort and controls.
For a comprehensive description of the patient cohort and controls, see the Online Supplement including Tables I, II , and III.
Elevated P-AFOS levels can interfere with interpretations of purinergic signaling, especially CD73.
Before further analysis, the cohort was screened for increased P-AFOS levels. The reference values of the local hospital laboratory were used with an upper threshold of 105 U/L (international units per liter). As P-AFOS is elevated in acute hepatobiliar diseases, and bone-related disorders, it was our assumption (and unpublished data) that these diseases, especially hepatobiliar diseases, may have a significant effect on purinergic signaling without contributing significantly to atherosclerosis. Thus, the markers of purinergic signaling could be misinterpreted as a result of another underlying illness. Altogether, 12 patients with elevated P-AFOS were noted. In six of these patients, P-AFOS was only marginally over the threshold, and no underlying condition explaining this could be seen in the patient files. All these six patients were included in the final analysis. Six patients with clearly elevated P-AFOS levels (one patient with liver cirrhosis, two patients with chronic pancreatitis, and three patients with prostate carcinoma and bone metastases) were identified and excluded from the final statistical analyses. P-AFOS concentrations positively correlated with CD39 levels ( Figure 1A ). An even stronger positive correlation was observed with CD73 ( Figure 1B) . A slightly negative correlation was noted for P-AFOS with ATP and ADP ( Figure  1C and D) . The correlations of CD39, ATP, and ADP with P-AFOS were abolished after exclusion of the six previously mentioned patients with marked background illnesses. A positive correlation persisted for only P-AFOS and CD73 (Pearson r = 0.226, P < 0.001).
Markers of purinergic signaling are elevated in the patient cohort.
Normal serum CD39 activity is 12-20 nmol/mL/hr, and CD73 activity is 120-280 nmol/mL/hr. [20] [21] [22] [23] The control group displayed consistently normal levels of CD39 and CD73 activity (Table 1) . CD39 activity did not significantly differ between the PAD patients and the control group (P = 0.09), but CD73 activity was significantly higher in the patient cohort (P < 0.0001) than in the controls. Normal plasma ATP and ADP values are generally within a 500-3000 nmol/L range. 20, 21 Again, the control group displayed consistently normal levels of ATP and ADP (Table 1) . Both ATP and ADP were clearly higher in the patient cohort than in the controls (P < 0.0001). There were no significant differences between genders amongst patients (data not shown). CD39 was rather normally distributed, but for CD73, ATP and ADP some patients had extremely high values, which skewed the distribution; thus log-transformed values were used to calculate statistical significance.
For further insight and analysis, the patient cohort was divided into previously derived age groups (<60, 60-69, 70-79, and >80 years) and into distinct clinically relevant subgroups of PAD depending on the localization of the disease (aorta-iliac, femoropopliteal, crural, or pedal). More proximal disease localizations tended to associate with higher ATP and ADP levels, and higher CD39 activity (see Figure  2A) . However, despite this prominent trend, using log-transformed values and linear regression only CD39 showed a declining trend towards distal PAD (P = 0.017). All PAD localization categories significantly differed from the control group for ATP and ADP, but not for CD39 (Figure 2A ). CD73 activity did not show any meaningful trend depending on PAD localization, but aorta-iliac (P = 0.0002), femoropopliteal (P < 0.0001) and crural (P = 0.042) groups significantly differed when compared to healthy controls (data not shown).
For patients of a younger age, ATP/ADP levels and CD39 activity tended to be higher than those of older age groups (see Figure 2B) . However, only CD39 showed declining linear trend towards older age in patients (P = 0.055) and in controls (P < 0.0001). Different age groups were compared directly against their age-matched controls, and all showed clear statistically significant differences ( Figure 2B ). CD73 activity did not show any meaningful trend across age groups, and only patients in age group 70-79 showed a significant increase (P = 0.003) when compared to its corresponding control group (data not shown).
Correlation of markers of purinergic signaling with dyslipidemia, hypertension, and hyperglycemia.
Since cardiovascular risk factors are known to associate with different PAD localizations, it was our assumption that certain risk factors could affect purinergic signaling and lead to an atherosclerotic disease. Thus, we tested potential correlations of cholesterol levels, triglycerides, systolic blood pressure, glycemia, and creatinine levels against markers of purinergic signaling and found that several known risk factor related elements positively correlated with ATP and ADP concentrations in PAD patients, but not in controls without clinically evident PAD.
The most pronounced results of these tests amongst patients are presented in Figure 3 . Systolic blood pressure (P = 0.043, Figure 3A ) and triglycerides (P = 0.048, not shown) had a statistically significant positive correlation with ADP concentration. Total cholesterol had a strong positive correlation with ATP concentration (P = 0.013, Figure 3C ) and CD39 activity (P = 0.003, Figure 3B ). Also triglycerides had a strong positive correlation with ATP (P = 0.005, not shown). To illustrate the effect of hyperglycemia, the GHbA1c value was used because it reflects a more constant elevation in blood glucose levels than a single fasting glucose value. ATP and ADP levels correlated positively with increased glucose levels as a measure of GHbA1c, but did not reach statistical significance ( Figure 3D ). Creatinine levels did not positively correlate with ATP or ADP in the patient cohort. We also performed the same testing with the control group. Systolic blood pressure, LDL cholesterol, triglycerides, and creatinine were not significantly correlated with markers of purinergic signaling (data not shown). Only total cholesterol had a slight positive correlation with ATP (P = 0.026).
Active smoking is associated with high ATP and ADP levels and increased CD39 activity in PAD patients.
To examine the effect of smoking on purinergic signaling as a cardiovascular risk factor, we formed subgroups from PAD patients with only one distinct cardiovascular risk factor: smoking, hypertension, dyslipidemia, or diabetes (see Table IV in the Online Supplement for subgroup characteristics). Especially ADP tended to be higher in PAD patients with only smoking as a cardiovascular risk factor when compared to other PAD subgroups with one distinct risk factor (see Table 2A ). Smoking did not elevate ATP and ADP levels in control subjects without clinically evident PAD (data not shown). ATP (P < 0.0001) and ADP (P < 0.0001) levels were clearly higher and CD39 to some extent higher (P = 0.043) in smoking PAD patients when compared to smoking controls (Table 2B) . Similarly, we also tested PAD patients who had only dyslipidemia as a risk factor against control subjects with dyslipidemia. Control subjects with clear dyslipidemia had significantly lower ATP (P = 0.015) and ADP (P = 0.0475) when compared to PAD patients with only dyslipidemia as a risk factor (Table 2C ).
The entire patient cohort was further tested for the effect of smoking on all markers of purinergic signaling. CD39 activity steadily increased with the degree of smoking: patients who had never smoked (mean, 16.4; SD, 6.4 nmol/mL/hr), had quit smoking (mean, 17.9; SD, 5.5 nmol/mL/hr) or were active smokers (mean, 20.3; SD, 7.7 nmol/mL/hr). Active smokers had significantly higher CD39 activity than those who had smoked but quit (P = 0.041) or those who had never smoked (P = 0.001), using the Student's t-test.
Low CD39 activity is associated with disease progression.
CD39 activity was significantly lower in patients with critical ischemia (n = 118; mean, 17.3; SD, 6.5 nmol/mL/hr) than in patients with claudication (n = 97; mean, 19.3; SD, 6.9 nmol/mL/hr) using Student's t-test (P = 0.025). This suggests that higher CD39 activity could protect from disease progression to critical ischemia. However, this could also be associated with an increasing severity of ischemia because CD39 activity steadily decreased from Rutherford values of 1 to 6 (i.e., from mild claudication to major tissue loss) giving a correlation (Spearman) of ˗0.174 (P = 0.01). Other markers did not show any correlations.
Similarly, patients with severe coronary artery disease (CAD) (mean, 17.7; SD, 7.6 nmol/mL/hr) had lower CD39 than patients with mild CAD (mean, 19.1; SD, 6.3 nmol/mL/hr), but this was not statistically significant (P = 0.264).
Explorative statistical modeling of multiple background variables related to high or low levels of ATP and ADP, or CD39 and CD73 activity.
In accordance with the previously presented trends of increased ATP and ADP levels, and CD39 and CD73 activity in the patient cohort, explorative statistical modeling of multiple background variables was performed (by linear regression) to gain more insight on which variables affect marker levels. For this, only the patient cohort was used, with log-transformed values for purinergic markers. All of the statistically significant findings are summarized in Table 3 .
The first column, "Full combined model", indicates all variables, which showed some significance in their respective group analysis (demographic factors, cardiovascular risk factors, and medication) and were used in the final combined reduction model. The second column, "Reduced combined model", shows variables that remained significant. For ATP, only high P-AFOS levels and the use of angiotensin receptor blockers (ARBs) were associated with low levels of ATP. Similarly for ADP, high P-AFOS was associated with low values, but the relationship was not as strong as that of ATP. For ADP, younger age and hypertension were associated with high values, and the use of statin medication was associated with low values. Despite this finding, no association between the use of statins and CD39 activity was detected. No associations between CD39 and medications were detected at all. For CD39 only smoking and uremia were significant in the final combined model. Out of all of the markers, CD73 had the strongest and most diverse associations with different factors. The most pronounced phenomenon was the association of high CD73 activity with chronic hypoxia, i.e., severe COPD, but not to milder COPD or smoking. In addition, higher P-AFOS levels strongly associated with increased CD73 activity, as already noted in Figure 1 . Surprisingly, the use of warfarin was associated with increased CD73 activity, as was female gender. When medications alone were tested, the use of statins had the strongest association with increased CD73 activity (data not shown), but this effect was to some extent diminished in the final combined model, in which warfarin exhibited a stronger association.
DISCUSSION
We hypothesized that malfunctions of CD73-derived extracellular adenosine production would contribute to atherosclerosis and that this effect would be observed in our PAD patient cohort. Instead, throughout our patient cohort, we observed high CD73 activity, and to some extent CD39 activity as well. Elevated CD73 was especially associated with hypoxemic atherosclerotic disease, while elevated CD39 was associated with smoking and ATP/ADP-dependent entities. All markers of purinergic signaling were normal in the controls, and values of ATP, ADP, and CD73 were significantly higher in atherosclerotic patients. CD39 activity was not significantly increased in the patient cohort as a result of the high CD39 activity in the youngest control population (controls <40 years, Figure 2B ). The youngest control group with the highest CD39 activity also had the lowest ATP and ADP levels (see Figure 2B ).
Our findings are in line with previous studies of the role of CD39 and ATP/ADP interplay in thrombosis and vascular inflammation. 24, 25 It is also well-documented from lung tissue and bronchial fluid samples that purinergic markers, especially CD73, are elevated in the presence of COPD and hypoxia, 26, 27 and in in vivo animal studies demonstrating the effects of CD73 in hypoxia transduction. 17 In the present study, the same effects were observed in blood samples from PAD patients. However, CD73 activity was clearly more associated with a chronically hypoxic state than CD39 activity, and CD39 activity had a stronger relationship with active smoking, which could be interpreted as intermittent hypoxia. Both CD73 and CD39 expression and activity can be driven by hypoxia, 28 but as seen here and before, 29 CD39 is somewhat unaffected by chronic hypoxia, but instead intermittent hypoxia can have an effect.
However, the increased ATP and ADP levels in systemic circulation of the studied patients may reflect diminished endothelial bound ecto-nucleotidase levels in the vascular wall. Similar experimental results were reported previously both in young atherosclerosis-prone apolipoprotein E-deficient mice 26 and in chronically hypoxic bovine vasa vasorum endothelial cells.
29
A similar underlying pathological mechanism may occur in the atherosclerotic hypoxic vessels observed in the patient cohort of this study. Lost ecto-nucleotidases from the vascular wall could be reflected in the high circulating levels observed herein.
Notably, NTPDase1/CD39 and other nucleotidases may circulate in the bloodstream either as "true" soluble enzymes 16, 21 or in the form of microparticle-embedded enzymes 30 . Similar patterns of nucleotide metabolism were observed in human serum and heparinized plasma, and also after additional ultracentrifugation of serum samples for 1 hr at 100,000 g 21 (and our unpublished data). These data exclude the potential release of membrane-bound nucleotidases from the blood elements in the course of serum preparation and provide further evidence for the predominant contribution of soluble rather than microparticle-associated enzymes to the measured NTPDase/ADPase and ecto-5'-nucleotidase/CD73 activities.
The results of this study indicate that in a general population of patients with PAD, it is not the impairment of CD39 and CD73 that contributes to atherosclerosis, but it is the burden of circulating ATP and ADP that plays a more determinant role in the pathogenesis of the disease. This mechanism is especially notable in young patients. Old age, which is a known major independent risk factor for PAD, does not seem to play a significant role within this mechanism. Alternatively, age-related impairments (e.g., of CD39), even in the absence of increased levels of ATP and ADP, could be a contributing factor. It is a well-known clinical observation amongst practitioners of vascular surgery, as also demonstrated by Diehm et al., 31 that smoking is associated with proximal PAD in young patients, while old age is often associated with a distal disease. Now, for the first time, our findings demonstrate that this clinical phenomenon is connected to changes at a molecular level.
All atherosclerotic patients in this cohort displayed relatively high levels of ATP and ADP when compared to those of the controls and known normal levels derived from past experiments. 20, 21 Distinct cardiovascular risk factors were shown to drive the increase in ATP and ADP levels amongst subjects with a clinically significant atherosclerotic disease, but not amongst the controls. However, in the multivariable modeling, high ATP levels could not be clearly appointed to any specific cardiovascular risk factor, and ADP could only be appointed to hypertension. ATP and ADP appeared to be especially high in proximal PAD and younger age, but to some extent this phenomenon lacked strength after log-transformation. This observation could, however, strongly associate with smoking. ADP was clearly higher in patients who had only smoking as a cardiovascular risk factor when compared to smoking controls and other risk factorbased subgroups. PAD patients with only diabetes as a risk factor, on the other hand, had the lowest ATP and ADP levels and amongst the cardiovascular risk factor-related laboratory values, hyperglycemia had the weakest correlation with ATP and ADP. An explanation to this weak association could be that, in practice, diabetes is mostly associated with distal PAD, while smoking, dyslipidemia, and hypertension are associated with proximal PAD. 31 Thus, ATP and ADP could be a common denominator of molecular pathophysiology amongst several cardiovascular risk factors, although smoking may be the strongest driver for both of these factors, especially ADP.
In addition to high levels of ATP and ADP, smoking patients exhibited significant CD39 activity. This could indicate that CD39 activity is required to clear the elevated levels of ATP and ADP caused by smoking. It would be logical to assume that without an elevated level of CD39 activity, ATP and ADP levels would be even higher in smoking patients. Lower CD39 activity could contribute to disease progression amongst PAD patients. Such an effect was observed when comparing patients with claudication to those with critical ischemia. Lower CD39 activity was observed in patients with critical ischemia, and CD39 activity decreased steadily as the disease progressed according to the Rutherford classification. In previous studies, soluble CD39 exhibited significant antithrombotic effects. 15, 16, 32 Building on clinical knowledge and past findings, it is known that smoking has a highly damaging effect on lower extremity vascular bypass grafts. Smoking independently increases the risk of graft failure by up to 4-fold. 33 It was recently shown that smokers with atherosclerotic diseases benefit more from antiplatelet therapy targeting the P2Y 12 -receptor than non-smoking atherosclerotic patients. However, the mechanism remains unknown.
34-36
The effect of smoking on cytochrome P450 (CYP)1A2, which converts clopidogrel into its active metabolite, was provided as a rationale, 37 but this does not explain a similar smoker's paradox observed with prasugrel and ticagrelor, which have different mechanisms of action.
38
On the basis of our findings, we suggest that the beneficial effect is specifically due to the inhibition of ADP via the P2Y 12 receptor expressed on platelets because circulating ADP levels are elevated in smokers.
Moreover, statins are known to have anti-inflammatory and antithrombotic effects. A suggested mechanism of action could be an improvement in CD39 activity. 39 In the present study, the use of statins was not associated with CD39 activity, but the use of statins was clearly associated with lower ADP levels. We already observed a similar phenomenon in a prospective setting in which young diabetic patients exhibited low ADP values after statin therapy, but no change in CD39 activity. 40 As Kaneider et al. showed in an in vitro study, statins restored impaired CD39 function. 39 They also did not report increased levels of expression. Thus, it could be that the beneficial effects of statins are directed to CD39 on the vascular wall and are only observed as changes in nucleotide, but not NTPDase, levels when measuring circulating values. However, as noted in the present study, and as shown earlier, statins improve CD73 expression, although the effect is only transient.
40,41
An explanation could be that statins inhibit Rho-GTPase-dependent endocytosis of ecto-nucleotidases 41 but lack the ability to induce new protein synthesis.
The use of antihypertensive ARBs, however, was clearly associated with low ATP values amongst the patient cohort. This could to some extent explain the beneficial effects in cardiovascular events associated with the use of ARBs. 42, 43 However, on the basis of our results, this is currently an entirely theoretical interpretation.
In conclusion, we showed, for the first time, changes in intravascular nucleotide turnover in different subgroups of patients suffering from PAD and related cardiovascular risk factors. We believe that our findings indicate an important role for purinergic signaling during the atherosclerotic process, particularly contributing to atherosclerotic diseases associated with a younger age, tobacco smoking, and thrombosis.
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Novelty and Significance
What Is Known?
 Purinergic signaling plays an important role in inflammation and vascular wall integrity.
 Impairment of the signaling cascade may lead to atherosclerosis.
 Smoking is the leading cause of lower extremity vascular bypass graft failure.
What New Information Does This Article Contribute?
 Purinergic signaling, i.e., ATP metabolism, plays an important role in the development of peripheral artery disease at a young age and affects large arteries (aorta-iliac or femoropopliteal arteries).
 Smoking is associated with elevated ATP/ADP levels and disease burden.
 Cardiovascular patients who continue to smoke could benefit from permanent ADP/P2Y 12 antiplatelet therapy, especially if they have a vascular bypass.
In general, little is known about purinergic signaling in atherosclerosis, especially in peripheral artery disease (PAD). In this study, we provide evidence that the pro-thrombotic effect of tobacco smoke is due to elevated plasma ADP levels. Our findings provide evidence for a mechanism underlying the greater beneficial effects of clopidogrel-like antiplatelet therapy in smokers than non-smoking patients. The use of P2Y 12 antiplatelet therapy for vascular bypass graft protection in PAD patients who smoke should be tested in a prospective randomized study.
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ONLINE SUPPLEMENT
Methods
Patient Cohort
For the 226 subjects forming the patient cohort, all major demographic factors, baseline characteristics, cardiovascular risk factors, and medications were recorded, in addition to specific data on the severity and distribution of PAD. Disease severity was classified according to the Rutherford classification and then converted to the usual clinically relevant three categories: no symptoms (Rutherford 0), claudication (Rutherford 1-3), and critical ischemia (Rutherford 4-6). Elective patients with minor ulcers or dry peripheral gangrene of a small area, e.g., one to two toes, were included in the study, but patients with infections or tissue loss leading to transmetatarsal amputation were not included. Baseline characteristics and cardiovascular or risk factors were determined on a yes/no basis, if recorded in the patient file. Type I and type II diabetic patients were evaluated separately, but also together as a single variable of three categories: no diabetes, diabetics on oral medication, and diabetic patients treated with insulin. Patients with coronary artery disease (CAD) were also assigned in a variable of three categories: i) no diagnosis or symptoms, ii) diagnosed and only mildly symptomatic (no invasive treatment or history of acute myocardial infarction, AMI), and iii) symptomatic (previous AMI or invasive treatment received). All autoimmune and rheumatic diseases were reported (e.g., systemic lupus erythematosus, psoriasis, inflammatory bowel disease, etc.), but the prevalence was so small that an overall "rheumatic disease" variable was formed. Patients with dyslipidemia were either already diagnosed and on statin therapy, or were newly diagnosed according to the current national guidelines (based on cholesterol and triglyceride levels) and were prescribed statin therapy during the index hospital stay.
Patients were divided into the following age groups (<60, 60-69, 70-79, and >80 years) and categorized according to the distribution of disease burden in the lower extremities (aorta-iliac, femoropopliteal crural, and pedal). Patients could exhibit calcification at several levels, but a distinct category was assigned if one area was proven to be clearly affected according to the Inter-Society Consensus on the Management of Peripheral Artery Disease (TASC II) -classification and the practicing vascular surgeon. Only one patient was excluded from categorization as a result of several levels of significant atherosclerotic lesions.
Non-atherosclerotic Control Cohort
Sixty-four newly recruited volunteers were all screened by a practicing medical doctor of the research group for symptoms and signs of PAD. A palpable pedal pulse was used to determine whether subjects were without evidence of clinically evident PAD. Eighty-nine subjects (73 males, 16 females) were selected from the FINRISK 1997 study based on age (35-74 years), health status, and residence in either Southern Finland (Helsinki and Vantaa) or Eastern Finland (Province of North Karelia). A member of the research group did not see these subjects. The subjects had to be free of CHD, PAD, stroke, diabetes, cancer, COPD, and rheumatic illnesses on the basis of both a self-report and register linkage and national health care databases. These 89 subjects from FINRISK 1997 and the 64 new volunteers without clinically evident PAD formed the control pool (n = 153) for the PURE ASO patient cohort and were divided into age groups to match the patient cohort: <40 (n = 81), 40-59 (n = 16), 60-69 (n = 40), and 70-79 (n = 16) years. The oldest age group (>80) could not be matched. Standard deviation in parentheses. Lipid levels are expressed as mmol/L, systolic blood pressure (Syst BP) in mmHg and age in years. Chol, total cholesterol; Trig, triglycerides.
<60 years
